Nasdaq · CIK 0001682852 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Moderna, Inc.
MRNA chart by TradingView
PRICE HISTORY
LIVE · NASDAQMRNA chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $1.9B
- EBITDA
- $-2.9B
- FREE CASH FLOW
- $-2.1B
- EPS
- $-7.25
- GROSS MARGIN
- 55.35%
- ROIC
- -42.47%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 34 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
-59%4.1x94.2x
⤢
P / SALES (TTM)
12.5x
-88%2.3x230.6x
⤢
P / BOOK
4.1x
-25%1.1x16.5x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
12.0x
+146%4.9x12.0x
⤢
FCF YIELD (TTM)
-4.46%
+3.1pp-36.77%17.76%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.1B
+399%⤢
EBITDA (DERIVED)
$-0.8B
$0.7B⤢
NET INCOME
$-0.8B
$0.7B⤢
EPS (DILUTED)
$-1.96
$1.59⤢
REVENUE GROWTH YOY
2.11%
+46.9pp-92.76%24112.50%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
-388.28%
+105.2pp-1400.00%556.69%
⤢
RETURN ON CAPITAL
-55.98%
-13.5pp-55.98%-42.47%
⤢
RETURN ON EQUITY (TTM)
-46.61%
-21.5pp-50.09%86.26%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN35.86%
OPERATING MARGIN-562.07%
NET MARGIN-539.31%
FCF MARGIN-388.28%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$-0.6B
$0.4B⤢
STOCK-BASED COMP
$0.1B
+913%⤢
CAPITAL EXPENDITURE
$0.0B
+16%⤢
SHARES OUTSTANDING
0.40B
+20%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$1.7B
+1804%⤢
TOTAL DEBT
$0.6B
+0%⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 78.48%INSIDERS 7.25%OTHER / RETAIL 14.26%1,072 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| FMR, LLC | 11.44% | 45.7M | $2.70B | +62.8% |
| Blackrock Inc. | 7.42% | 29.6M | $1.75B | -8.8% |
| Vanguard Capital Management LLC | 5.73% | 22.9M | $1.35B | NEW |
| Capital World Investors | 4.68% | 18.7M | $1.11B | +45.8% |
| BAILLIE GIFFORD & CO | 4.56% | 18.2M | $1.08B | -8.9% |
| Vanguard Portfolio Management LLC | 3.91% | 15.6M | $924.0M | NEW |
| State Street Corporation | 3.72% | 14.9M | $879.3M | -9.2% |
| Geode Capital Management, LLC | 2.36% | 9.4M | $558.3M | +2.3% |
| Two Sigma Investments, LP | 2.28% | 9.1M | $537.6M | +23.8% |
| Morgan Stanley | 2.12% | 8.5M | $501.2M | -4.5% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.